Foundation Medicine Inc. and Eli Lilly and Company entered a collaboration for the development of Foundation Medicine’s tissue- and blood-based assays as companion diagnostics for Retevmo (selpercatinib) and other therapies in Loxo Oncology at Lilly’s pipeline.
Table of Contents
THE CLINICAL CANCER LETTER
YOU MAY BE INTERESTED IN
Pierre Fabre Laboratories and Vernalis, a fully owned subsidiary of HitGen Inc., established a long-term partnership to identify pre-clinical candidates against oncology targets.
Pierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies.
Veeva Systems formed a ten-year strategic partnership agreement with Merck, that builds on the existing 12-year partnership between the companies. Under the terms of the agreement, Merck will take a Veeva-first approach to new industry-specific software and data, selecting Veeva products when they are fit for purpose to maximize the value of Veeva’s integrated, cloud-based platform and products.
Carrum Health and AccessHope LLC formed a collaboration to bring cancer expertise to people living with cancer.
Indivumed GmbH and CELLphenomics GmbH have formed a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets.